Moreover, the HGF-MET duo modifies central and peripheral immune functions (Benkhoucha et al., 2010), which are emerging as the key regulators of AD pathogenesis (Labzin et al., 2018; Ising et al., 2019; Gate et al., 2020). This evidence concerns the gene MET and Alzheimer disease.